Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer?
Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline–docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0% of control patients and 3.7% of docetaxel-treated patients. CNS relapse occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of patients survived 1 year from the diagnosis of CNS relapse. Prog
Related Questions
- Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer?
- Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
- Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?
